Lipocine Inc.
LPCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
In the last 90 days, Lipocine Inc. insiders filed 3 open-market purchases and 0 sales; 37 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:52 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $9.63M (487.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 18, 2026 | – | Mar 7, 2024 | – | – |
| Revenue | $1.98M | $11.2M | -$2.85M | $500.0K | $16.1M |
| Operating expenses | $12.3M | $12.4M | $15.1M | $12.6M | $13.0M |
| Research and development | $8.58M | $7.35M | $10.2M | $8.56M | $7.67M |
| Selling, general and administrative | $3.76M | $5.00M | $4.90M | $4.06M | $5.33M |
| Operating income | -$10.4M | -$1.16M | -$17.9M | -$12.1M | $3.15M |
| Interest expense | – | – | – | $27.1K | $203.3K |
| Income tax | $200 | $681 | $755 | $681 | $200 |
| Net income | -$9.63M | $8.35K | -$16.4M | -$10.8M | -$634.4K |
| EPS, basic | $-1.77 | – | $-3.10 | $-0.12 | $-0.01 |
| EPS, diluted | $-1.69 | – | $-3.14 | $-0.13 | $-0.01 |
| Weighted shares, basic | 5.45M | 5.34M | 5.27M | 88.5M | 86.9M |
| Weighted shares, diluted | 5.71M | 5.42M | 5.27M | 88.9M | 86.9M |
| Margins and growth | |||||
| Operating margin | -524.7% | -10.3% | – | -2423.9% | 19.5% |
| Net margin | -487.1% | 0.1% | – | -2151.7% | -3.9% |
| Revenue growth, year over year | −82.3% | – | −670.2% | −96.9% | – |
| Net income growth, year over year | −115,371.9% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 18, 2026 | – | Mar 7, 2024 | – | – |
| Cash and equivalents | $5.21M | $6.21M | $4.77M | $3.15M | $2.95M |
| Total current assets | $16.9M | $22.3M | $22.9M | $34.1M | $46.4M |
| Property, plant and equipment | $104.3K | $165.1K | $116.1K | $131.6K | $7.21K |
| Total assets | $17.0M | $22.5M | $23.0M | $37.5M | $52.5M |
| Accounts payable | $971.8K | $271.7K | $1.40M | $600.4K | $1.29M |
| Short-term debt | – | – | – | – | $2.31M |
| Total current liabilities | $2.53M | $1.51M | $2.63M | $1.68M | $5.62M |
| Long-term debt | – | – | – | – | $1.67M |
| Total liabilities | $2.53M | $1.51M | $2.63M | $1.91M | $6.91M |
| Shareholders' equity | $14.5M | $21.0M | $20.4M | $35.6M | $45.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 18, 2026 | – | Mar 7, 2024 | – | – |
| Operating cash flow | -$9.76M | -$1.22M | -$11.9M | -$12.0M | -$4.41M |
| Capital expenditures | – | $90.1K | $13.2K | $133.8K | $7.59K |
| Free cash flow | – | -$1.31M | -$11.9M | -$12.1M | -$4.42M |
| Depreciation and amortization | $60.8K | $41.1K | $28.7K | $9.45K | $380 |
| Stock-based compensation | $242.5K | $408.6K | $654.4K | $636.1K | $603.9K |
| Investing cash flow | $5.89M | $2.45M | $13.1M | $14.3M | -$43.8M |
| Financing cash flow | $2.87M | $209.3K | $404.6K | -$2.13M | $26.9M |
| Net change in cash | -$1.00M | $1.43M | $1.62M | $197.9K | -$21.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 12.3% | 3.6% | – | 127.2% | 3.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-17 in Q2 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.